26.94

1.16% 0.31

After Hours: 26.94

Evommune Inc (EVMN)

Overview News Price History Discussions Forecast

Evommune Inc stock is traded at $26.94, with a volume of 181.07K. It is up +1.16% in the last 24 hours and up +22.51% over the past month. Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Previous Close:

$26.63

Open:

$26.67

24h Volume:

181.07K

Relative Volume:

0.30

Market Cap:

$970.33M

Revenue:

$13.00M

Net Income/Loss:

$-68.87M

P/E Ratio:

-12.09

EPS:

-2.2276

Net Cash Flow:

$-76.68M

1W Performance:

-0.70%

1M Performance:

+22.51%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$26.02

$27.39

1-Week Range:

$25.00

$28.82

52-Week Range:

$13.88

$33.20

Evommune Inc Stock (EVMN) Company Profile

Name

Evommune Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(650) 223-7745

Address

1841 PAGE MILL RD, PALO ALTO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

EVMN's Discussions on Twitter

Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EVMN Evommune Inc	26.94	959.17M	13.00M	-68.87M	-76.68M	-2.2276
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Evommune Inc Stock (EVMN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Resumed	Oppenheimer	Outperform
Jan-22-26	Initiated	Oppenheimer	Outperform
Jan-08-26	Initiated	Raymond James	Strong Buy
Jan-06-26	Initiated	H.C. Wainwright	Buy
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight
Dec-01-25	Initiated	Evercore ISI	Outperform
Dec-01-25	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight
Dec-01-25	Initiated	William Blair	Outperform

View All

Evommune Inc Stock (EVMN) Latest News

Apr 14, 2026

Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights

Apr 14, 2026

MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart

Apr 14, 2026

William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo

Apr 14, 2026

Apr 13, 2026

Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks

Apr 13, 2026

Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks

Apr 13, 2026

Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan

Apr 13, 2026

Apr 11, 2026

RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail

Apr 11, 2026

Apr 10, 2026

Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat

Apr 10, 2026

Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com

Apr 10, 2026

Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus

Apr 10, 2026

Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat

Apr 10, 2026

RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo

Apr 10, 2026

Apr 09, 2026

Evommune (EVMN) Institutional Ownership 2026 - MarketBeat

Apr 09, 2026

Apr 07, 2026

Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media

Apr 07, 2026

Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo

Apr 07, 2026

Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat

Apr 07, 2026

Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat

Apr 07, 2026

Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice

Apr 07, 2026

Oppenheimer initiates Evommune stock rating at Outperform, $50 target By Investing.com - Investing.com Australia

Apr 07, 2026

Oppenheimer initiates Evommune stock rating at Outperform, $50 target - Investing.com

Apr 07, 2026

Apr 06, 2026

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine - PharmiWeb.com

Apr 06, 2026

Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN - MarketBeat

Apr 06, 2026

Apr 05, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Apr 05, 2026

Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - marketbeat.com

Apr 05, 2026

Apr 04, 2026

Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal

Apr 04, 2026

Apr 03, 2026

EVMN 8-K & SEC Filings - Yahoo Finance Australia

Apr 03, 2026

Mar 31, 2026